Last updated: November 3, 2026
Tepotinib hydrochloride, marketed as Tepmetko by Merck KGaA and EMD Serono, is a targeted therapy for metastatic non-small-cell lung cancer with MET exon 14 skipping alterations. Its commercial outlook depends on a small but clinically defined biomarker population, adoption of molecular testing, competition from capmatinib, treatment durability, and reimbursement. Public filings do not report Tepmetko revenue as a standalone product, so its financial trajectory is best assessed through launch expansion, indication potential, and the performance of Merck KGaA’s Healthcare segment.
What is tepotinib hydrochloride used for?
Tepotinib is an oral MET tyrosine kinase inhibitor. In the United States, Tepmetko is approved for adults with metastatic non-small-cell lung cancer whose tumors have MET exon 14 skipping alterations, as detected by an FDA-approved test.[1]
The US label recommends 450 mg once daily with food, supplied as two 225 mg tablets. The product is designed for chronic oral treatment until disease progression or unacceptable toxicity.[1]
Tepotinib’s target market
MET exon 14 skipping alterations occur in approximately 3% to 4% of non-small-cell lung cancers, with higher prevalence in older patients and in sarcomatoid histologies.[2] The alteration is generally mutually exclusive with several common driver mutations, including EGFR and ALK alterations.
The commercial population is therefore narrower than the full lung cancer market. The addressable population expands when testing identifies patients who otherwise would receive platinum chemotherapy, immunotherapy, or non-targeted treatment.
Key market characteristics include:
| Market factor |
Commercial effect |
| MET exon 14 prevalence |
Limits the absolute patient population |
| Older patient population |
Supports demand for an oral targeted therapy |
| Molecular testing rates |
Determines diagnosis and treatment eligibility |
| Metastatic disease setting |
Allows treatment at initial diagnosis and after prior therapy |
| Chronic oral dosing |
Supports recurring product revenue |
| Disease heterogeneity |
Creates testing and response-management complexity |
| Small competing set |
Supports specialist prescribing but limits market size |
When did tepotinib receive FDA approval?
The FDA approved Tepmetko on February 3, 2021, for metastatic NSCLC with MET exon 14 skipping alterations.[1] The approval was based primarily on the VISION study, which used liquid biopsy and tissue biopsy to identify eligible patients.
Japan approved tepotinib before the United States. The Japanese approval helped establish early commercial use and clinical familiarity, while the US approval created the largest high-value market for the product.
The European Commission granted conditional marketing authorization in 2022 for advanced NSCLC with MET exon 14 skipping alterations after prior immunotherapy and/or platinum-based chemotherapy, or for patients unsuitable for these treatments.[3]
Regulatory timeline
| Date |
Event |
| 2020 |
Japan approval for MET exon 14 skipping NSCLC |
| February 3, 2021 |
FDA approval in the United States |
| 2021 |
US launch under the Tepmetko brand |
| 2022 |
European Union conditional marketing authorization |
| 2023-2024 |
Continued expansion of testing, treatment-center use, and real-world evidence |
The FDA approval included use with a companion diagnostic framework. Molecular identification remains essential because histology alone cannot select patients for tepotinib treatment.
How effective is tepotinib in MET exon 14 skipping NSCLC?
Tepotinib demonstrated clinically meaningful response activity in the VISION study. In the FDA label, the confirmed objective response rate was approximately 43% across evaluable patient groups, with responses observed in both tissue-biopsy and liquid-biopsy cohorts.[1]
Median duration of response was approximately 10.8 months in the principal efficacy analysis.[1] These results support use in patients with an actionable MET exon 14 alteration, particularly where a targeted oral therapy is preferred.
Clinical value is strengthened by:
- Activity in previously treated and treatment-naive patients.
- Oral administration.
- A biomarker-defined indication.
- Durable responses in a subset of patients.
- Use across different histologic subtypes of NSCLC.
The main limitations are the single-arm nature of the pivotal evidence, the small biomarker population, variable assay sensitivity, and toxicity management.
Key adverse events affecting commercial use
The most commercially relevant adverse events are peripheral edema, nausea, diarrhea, fatigue, dyspnea, decreased appetite, and hepatotoxicity.[1] Interstitial lung disease or pneumonitis is a serious but less frequent risk. Dose interruption and dose reduction can affect persistence and treatment economics.
Peripheral edema is particularly relevant because it can lead to treatment modification and may require supportive care. Physicians familiar with MET inhibitors generally view toxicity management as manageable, but it remains a prescribing consideration when comparing tepotinib with capmatinib or chemotherapy.
How large is the tepotinib market?
The market is commercially attractive on a per-patient basis but limited in total volume. MET exon 14 skipping NSCLC is a precision-oncology niche rather than a broad lung cancer franchise.
A simplified US market framework is:
| Variable |
Directional assessment |
| Total annual US NSCLC diagnoses |
Large |
| Metastatic NSCLC share |
Material |
| MET exon 14 share |
Low single digits |
| Diagnosed and tested population |
Growing |
| Eligible treated population |
Smaller than the mutation-positive population |
| Treatment duration |
Potentially several months to more than one year |
| Revenue model |
Recurring specialty-pharmacy and oncology sales |
The main growth lever is not a dramatic increase in disease prevalence. It is improved testing of newly diagnosed and previously treated patients. Broader use of comprehensive genomic profiling can identify MET exon 14 alterations that would otherwise remain undetected.
Testing and reimbursement as market drivers
Testing can occur through tissue-based next-generation sequencing or plasma-based liquid biopsy. Tissue testing may be constrained by inadequate samples, while liquid biopsy can accelerate treatment decisions when tissue is unavailable.
The commercial addressable market expands as:
- More patients receive broad genomic profiling at diagnosis.
- Plasma assays are used when tissue is insufficient.
- Community oncology practices adopt biomarker-directed treatment pathways.
- Payers reimburse comprehensive testing and targeted therapy.
- Physicians recognize MET exon 14 as a treatment-defining alteration.
The market contracts when testing is delayed, when patients deteriorate before molecular results return, or when payers restrict coverage based on line of therapy.
What companies compete with tepotinib?
Tepotinib competes most directly with capmatinib, marketed as Tabrecta by Novartis. Capmatinib also has FDA approval for metastatic NSCLC with MET exon 14 skipping alterations.[4]
Crizotinib, marketed as Xalkori by Pfizer, has an FDA indication for MET exon 14-positive metastatic NSCLC but has a less specialized commercial position and broader historical use across other kinase-driven cancers.[5]
Tepotinib versus capmatinib
| Attribute |
Tepotinib |
Capmatinib |
| Brand |
Tepmetko |
Tabrecta |
| Manufacturer |
Merck KGaA/EMD Serono |
Novartis |
| Target |
MET |
MET |
| US indication |
Metastatic NSCLC with MET exon 14 skipping alterations |
Same core biomarker indication |
| Route |
Oral |
Oral |
| Key commercial advantage |
Early US approval, global development, biomarker-focused positioning |
Strong oncology infrastructure and established targeted-therapy presence |
| Main commercial risk |
Small market and competition from Tabrecta |
Small market and overlapping clinical positioning |
The two drugs have not been compared in a head-to-head randomized trial. Prescribing can therefore depend on physician familiarity, diagnostic workflow, toxicity profile, payer policy, treatment sequencing, and local availability.
Other competitive pressures
Tepotinib also competes indirectly with:
- Platinum-based chemotherapy.
- Immune checkpoint inhibitors.
- Chemoimmunotherapy.
- Clinical trials.
- Off-label use of other MET-directed agents.
- Later-line targeted therapies for patients with resistant disease.
Amivantamab is not a direct substitute for MET exon 14 treatment because its principal approved use is in EGFR-driven NSCLC. It may still compete for oncology budgets and treatment slots within the broader targeted lung cancer market.
What is the financial trajectory for Tepmetko?
Merck KGaA does not generally disclose Tepmetko revenue as a separate audited product line in its public annual reporting. The product is reported within the Healthcare business, alongside a broader portfolio of oncology, neurology, fertility, and other medicines.[6]
The financial trajectory is therefore best described as a launch-to-expansion specialty-pharmaceutical profile:
| Phase |
Financial dynamic |
| 2020-2021 |
Initial revenue generation in Japan and the United States |
| 2022 |
European launch and broader geographic contribution |
| 2023-2024 |
Growth dependent on testing, treatment-center adoption, and repeat prescribing |
| Medium term |
Potential stabilization as a mature niche oncology product |
| Long term |
Exposure to patent expiry, generic entry, price pressure, and competing MET inhibitors |
Revenue growth is likely to be driven by volume rather than major price increases. Tepotinib already operates in a high-value oncology category, so additional sales should come primarily from diagnosis and treatment penetration.
Revenue sensitivity
Tepmetko revenue is sensitive to five variables:
- The number of patients receiving comprehensive molecular testing.
- The proportion of test-positive patients who receive tepotinib.
- Persistence on treatment.
- Relative positioning against capmatinib.
- Net price after rebates, discounts, and government programs.
The product has a favorable recurring-revenue structure because patients may remain on therapy for extended periods. Its revenue ceiling is constrained by the low prevalence of MET exon 14 skipping alterations and the availability of another approved MET inhibitor.
Geographic revenue exposure
The United States is likely to remain the most important single market because of high oncology drug pricing and an established precision-medicine infrastructure. Japan is strategically important because of earlier approval and a high concentration of lung cancer treatment. Europe offers geographic breadth but generally lower net pricing, country-specific reimbursement decisions, and slower uptake in some markets.
Emerging-market sales are limited by the cost of genomic testing, reimbursement constraints, and access to branded oncology medicines.
What patents protect tepotinib hydrochloride?
Tepotinib is protected by a combination of compound, pharmaceutical-composition, formulation, and potentially method-of-use rights. The relevant patent estate can differ by country and may include patent-term adjustment, supplementary protection certificates, pediatric extensions, and regulatory exclusivity.
The commercial protection analysis should separate:
- Active-ingredient patents.
- Salt, hydrate, or crystalline-form patents.
- Tablet and formulation patents.
- Methods of treating MET-driven cancers.
- Diagnostic or patient-selection claims.
- Manufacturing and process patents.
The drug is supplied as tepotinib hydrochloride hydrate. Salt and solid-state protection can be commercially important because an abbreviated applicant may need to address the specific active form used in the marketed product.
The FDA Orange Book and USPTO records are the controlling sources for US listing status, patent expiration, and Paragraph IV exposure. Public company filings and regulatory approvals do not establish a single worldwide loss-of-exclusivity date for Tepmetko.
Generic entry risk
Generic entry is more likely to begin with a Paragraph IV certification against listed US patents. A generic applicant could challenge:
- Compound claims.
- Salt or hydrate claims.
- Tablet formulation claims.
- Method-of-use claims covering MET exon 14 NSCLC.
Method-of-use patents can delay some forms of commercial entry, but their value depends on claim scope, labeling, induced-infringement risk, and the ability of a generic applicant to use a skinny label.
Tepotinib’s niche market may reduce the number of early generic challengers because development costs for a small oncology product must be justified against a limited patient pool. That factor can delay challenges, but it does not eliminate them.
What litigation and settlement risks affect tepotinib?
No major publicly established US patent settlement involving a generic tepotinib launch is identified in the core FDA approval and company materials cited here. The principal legal risks remain potential patent litigation, challenges to Orange Book listings, and disputes over the scope of method-of-use claims.
A Paragraph IV filing would create a potential 30-month stay under the Hatch-Waxman framework if the patent holder filed suit within the statutory period. The commercial effect would depend on the challenged patents, remaining patent term, and whether a settlement permitted an authorized or licensed generic launch.
Licensing is also relevant to commercial exposure. EMD Serono commercializes Tepmetko in the United States, while Merck KGaA’s global development and commercialization structure determines geographic rights. Public filings should be reviewed for country-specific commercialization arrangements, but the principal commercial identity remains Merck KGaA and EMD Serono.
How strong is the tepotinib commercial position?
Tepotinib has a strong scientific and regulatory position within the MET exon 14 niche, but a moderate overall commercial position.
Strengths
- Clear biomarker-defined FDA indication.
- Meaningful response rate and response duration.
- Oral dosing.
- Global regulatory approvals.
- Limited number of directly approved competitors.
- Ability to benefit from increased genomic testing.
Weaknesses
- Small eligible population.
- Overlapping indication with capmatinib.
- Toxicities that can require dose modification.
- Dependence on diagnostic access.
- No broad tumor-agnostic indication.
- Limited public revenue transparency.
- Future generic and patent-expiry exposure.
The product is more likely to become a durable specialty oncology asset than a multibillion-dollar franchise. Its strategic value may exceed its standalone revenue contribution if it strengthens Merck KGaA’s precision-oncology portfolio and creates commercial relationships with testing providers and oncology centers.
What generic launch scenarios exist for tepotinib?
Three launch scenarios are commercially plausible:
| Scenario |
Timing effect |
Market consequence |
| No early challenge |
Generic entry follows full patent and exclusivity expiry |
Branded revenue declines gradually |
| Paragraph IV challenge with settlement |
Entry occurs before all patents expire |
Price erosion begins earlier, potentially with limited competition |
| Successful patent defense |
Entry is delayed |
Tepmetko retains price and volume longer |
The depth of price erosion will depend on the number of entrants. A small patient population can produce fewer generic competitors, but oncology products often face rapid price pressure once multiple suppliers enter.
Key Takeaways
- Tepotinib hydrochloride is marketed as Tepmetko for metastatic NSCLC with MET exon 14 skipping alterations.
- The drug received FDA approval on February 3, 2021, after earlier Japanese approval.
- Its market is a high-value precision-oncology niche constrained by low biomarker prevalence.
- Capmatinib is the principal direct competitor; crizotinib remains an additional approved alternative.
- Revenue is recurring and specialty-driven, but Merck KGaA does not publicly report Tepmetko sales as a standalone audited product line.
- Growth depends more on genomic testing and treatment penetration than on expansion of the underlying disease population.
- The main financial risks are competing MET inhibitors, toxicity-related discontinuation, reimbursement pressure, and eventual generic entry.
- Patent value is likely distributed across compound, salt or hydrate, formulation, method-of-use, and manufacturing rights. Exact US loss-of-exclusivity timing must be determined from current Orange Book and patent records.
FAQs About Tepotinib Hydrochloride
Is tepotinib hydrochloride the same as Tepmetko?
Yes. Tepmetko is the branded product containing tepotinib hydrochloride hydrate as the active pharmaceutical ingredient.
Is Tepmetko approved for EGFR-mutated lung cancer?
No. Tepmetko is approved for metastatic NSCLC with MET exon 14 skipping alterations, not for EGFR-mutated disease.
Which is better, tepotinib or capmatinib?
There is no definitive head-to-head trial establishing superiority. Selection depends on clinical judgment, toxicity management, payer coverage, diagnostic results, and treatment history.
Can tepotinib be used after immunotherapy?
Yes. The VISION program included previously treated patients, and the European indication specifically covers patients treated with prior immunotherapy and/or platinum-based chemotherapy, or patients unsuitable for those treatments.[3]
Does tepotinib have biosimilar risk?
No traditional biosimilar pathway applies because tepotinib is a small-molecule drug. The relevant follow-on risk is conventional generic competition under the Hatch-Waxman framework in the United States.
References
-
U.S. Food and Drug Administration. (2021). Tepmetko (tepotinib) prescribing information. FDA.
-
National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Non-small cell lung cancer. NCCN.
-
European Medicines Agency. (2022). Tepmetko: EPAR - product information. EMA.
-
U.S. Food and Drug Administration. (2020). FDA approves capmatinib for metastatic non-small cell lung cancer. FDA.
-
U.S. Food and Drug Administration. (2021). FDA approves crizotinib for metastatic non-small cell lung cancer with MET exon 14 skipping alterations. FDA.
-
Merck KGaA. (2024). Annual report 2023. Merck KGaA.
